Amalgam Rx Appoints Medicare COO Jennifer Main as Chief Operating Officer and Chief Financial Officer
- World stocks edge back, bond yields, COVID-19 cases rise
- IBM (IBM) Tops Q1 EPS by 14c, Revenue Beats
- Oil hits $68 on Libya force majeure despite pandemic surge
- Oatly files for IPO; Plans to list on NASDAQ under the ticker 'OTLY' After 107% 2020 Revenue Growth
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Experienced Leader to Operationalize and Scale Digital Health Solutions
WILMINGTON, Del.--(BUSINESS WIRE)-- Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the appointment of Jennifer Main as chief operating officer (COO) and chief financial officer (CFO). On April 5, 2021, Ms. Main will join Amalgam Rx from Centers for Medicare and Medicaid Services (CMS) where she has served as COO, responsible for a wide range of functions, including financial management, information technology, acquisition, human capital, facilities, strategic planning, and enterprise risk management. Prior to that, she held senior executive titles, including that of CFO, in five different public and private organizations over the span of her 25+ year career.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005256/en/
(Photo: Business Wire)
Ms. Main served as CFO for the Troubled Assets Relief Program (TARP) at the United States Department of Treasury. Ms. Main led the design, development, and implementation of all areas of financial management for the $700 billion program, which was established to restore stability after the financial crisis of 2008. Previously, Ms. Main served in the roles of both COO and CFO at Millstein & Co., a boutique investment bank, between 2012 and 2016. Responsible for creating and managing all financial, human resources, and technology operations and systems to support the financial advisory and investment business, Ms. Main also served on the Board of Directors of DLT Solutions, a Millstein portfolio company. Millstein & Co. was acquired by Guggenheim Securities in 2018. Ms. Main also has startup experience as a founder of BusinessDataSource, which was later acquired by LoanChannel.
Ms. Main holds a master’s degree in public policy from Harvard University and a bachelor’s degree from Cornell University in history.
“Jenni Main is a talented operator who’s helped lead both private and public organizations, including CMS. Her extensive strategic, financial, and operational experience makes her the ideal person to help us bring Amalgam’s vision to life. She will be invaluable in helping Amalgam drive wide-scale adoption of its life-changing technologies. We’re thrilled she’s chosen to join our team,” said Ryan Sysko, chief executive officer and founder of Amalgam Rx.
“Having spent almost five years in leadership positions at CMS, I’ve seen firsthand the need for healthcare to continue to transform care delivery models and adopt outcomes-changing technology. From my perspective, Amalgam offers a new and different approach and has the potential to make a significant impact on quality and costs on a large scale. It’s an exciting time for Amalgam and I look forward to being part of the management team,” said Jennifer Main, newly appointed COO and CFO of Amalgam Rx.
“I have watched Amalgam’s impressive and swift growth over the last five years. Adding a superstar like Jenni Main will help facilitate that continuing trend as the company scales up and prepares for what’s next, including the launch of many amazing global partnerships and products,” said Jeff Courtney, board director of Amalgam Rx.
About Amalgam Rx
Amalgam Rx is the leader in bringing providers, life sciences, and digital solutions together. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Working in partnership with many of the world’s leading life sciences companies, Amalgam Rx has built an innovative platform for rapidly developing and scaling digital solutions — delivered through a wide variety of business models. Our proven end-to-end methodology enables the entire life cycle from R&D to commercialization. Amalgam’s solutions have generated more than 5 billion RWE data points utilized by patients and providers on three continents. For more information on how Amalgam Rx’s regulated, clinically validated technologies bring patients and providers closer together, reduce costs for payers, and unlock sustained value for partners, visit amalgamrx.com.
Source: Amalgam Rx, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fifth Third Announces First Quarter 2021 Results
- sureCore Unveils New Low Voltage Register Files
- Enviva Partners, LP Increases Revolver Capacity and Extends Credit Facility